| Name | Title | Contact Details |
|---|
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.
Health Media Lab is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioCentury Publications, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. BioCentury Publications, Inc. is based in Redwood City, CA. You can find more information on BioCentury Publications, Inc. at www.biocentury.com
Nueterra Capital is a private equity investment and advisory firm with an exclusive focus on healthcare. Leveraging a deep understanding of key industry drivers, Nueterra Capital invests in entrepreneurs with innovative minds, while providing professional expertise and back office resources to improve their bottom line performance and drive growth. Nueterra Capital has invested in hundreds of new ventures and continuously delivers the resources and strategic direction that allow our partners to advance and improve every aspect of healthcare.
Ridgeview institute is a Smyrna, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.